DULCOEASE

Adults and children 12 years and above:

Up to maximum of 500 mg should be taken daily in divided doses. Treatment should be commenced with large doses such as 100 mg three times daily, which should be adapted to the treatment response. Dulcoease is not recommended for use in children under the age of 12 years.

Duration of treatment The patient should be advised to consult a physician when constipation persists or worsens during treatment or when laxatives are needed for a long period of time. Method of administration Oral use. The capsules should be swallowed whole with a glass of water.

Special populations No specific dose adjustment is necessary for elderly patients.

01%; Not known (cannot be estimated from available data).

Gastrointestinal disorders • Rare:

Diarrhoea, nausea, abdominal cramps Skin and subcutaneous tissue disorders • Frequency unknown: Rash and pruritus Reporting of suspected adverse reactions Reporting suspected adverse reaction after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit / risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Organic disorders should be excluded prior to the administration of any laxative. 5 mg sorbitol per maximum recommended daily dose for adults. Patients with hereditary fructose intolerance (HFI) should not take this medicine. Dulcoease 100 mg Capsules contain E110 sunset yellow which may cause allergic reactions.

Dulcoease is contraindicated in patients with: - hypersensitivity to docusate or to any of the excipients - abdominal pain if not constipation-related - nausea and vomiting - intestinal obstruction